Literature DB >> 12044104

Treatment of generalized anxiety disorder.

Jack M Gorman1.   

Abstract

Generalized anxiety disorder (GAD) is characterized by chronic worry that may persist for many years. It is a debilitating disorder, and effective long-term treatment is required. Psychotherapy, particularly relaxation, cognitive therapy, and cognitive-behavioral therapy, has shown long-term benefit in GAD and may be a useful approach alone and as an adjunct to pharmacotherapeutic options. Available medications for GAD include benzodiazepine anxiolytics, buspirone, and antidepressants. Although benzodiazepines are effective as short-term anxiolytics, their use is compromised by a poor adverse event profile and, like buspirone, they lack the antidepressant efficacy important for addressing the comorbid depression experienced by many patients with GAD. Antidepressants, including paroxetine and the serotonin-norepinephrine reuptake inhibitor venlafaxine, are effective anxiolytics and resolve symptoms of depression in patients with GAD. The benefit of venlafaxine is sustained long term, enabling increased numbers of patients to attain remission from symptoms and experience restoration of normal functioning. Although further clinical studies are required to establish the use of psychosocial therapy in the treatment of GAD. preliminary results are encouraging. At present, the use of psychosocial therapy and second-generation antidepressants, such as some selective serotonin reuptake inhibitors and venlafaxine, offer the best approach to attaining long-term benefit for patients with GAD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044104

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Psychotherapy use in a privately insured population of patients diagnosed with a mental disorder.

Authors:  Ilan Harpaz-Rotem; Daniel Libby; Robert A Rosenheck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-02-16       Impact factor: 4.328

2.  Treatment of anxiety disorders in primary care practice: a randomised controlled trial.

Authors:  Christine A van Boeijen; Patricia van Oppen; Anton J L M van Balkom; Sako Visser; Pieter T Kempe; Nettie Blankenstein; Richard van Dyck
Journal:  Br J Gen Pract       Date:  2005-10       Impact factor: 5.386

3.  Pain adversely affects outcomes to a collaborative care intervention for anxiety in primary care.

Authors:  Natalia E Morone; Bea Herbeck Belnap; Fanyin He; Sati Mazumdar; Debra K Weiner; Bruce L Rollman
Journal:  J Gen Intern Med       Date:  2012-08-10       Impact factor: 5.128

4.  Symptomatic severity of PRIME-MD diagnosed episodes of panic and generalized anxiety disorder in primary care.

Authors:  Bruce L Rollman; Bea Herbeck Belnap; Sati Mazumdar; Fang Zhu; Kurt Kroenke; Herbert C Schulberg; M Katherine Shear
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

5.  Association between drug prescribing and quality of life in primary care.

Authors:  Samanta E Fröhlich; Anamaria V Zaccolo; Sabrina L C da Silva; Sotero S Mengue
Journal:  Pharm World Sci       Date:  2010-08-29

Review 6.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Patterns and correlates of benzodiazepine use in the French general population.

Authors:  Rajaa Lagnaoui; Fanny Depont; Annie Fourrier; Abdelillah Abouelfath; Bernard Bégaud; Hélène Verdoux; Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 8.  Molecular targets of anxiety: from membrane to nucleus.

Authors:  Long-Jun Wu; Susan S Kim; Min Zhuo
Journal:  Neurochem Res       Date:  2008-04-02       Impact factor: 3.996

9.  Diagnostic and symptom-based predictors of emotional processing in generalized anxiety disorder and major depressive disorder: An event-related potential study.

Authors:  Annmarie MacNamara; Roman Kotov; Greg Hajcak
Journal:  Cognit Ther Res       Date:  2015-08-30

10.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Trevor R Norman; James S Olver
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.